Susan W. Schwendner

Radioiodinated arylaliphatic ether analogues of cholesterol

Novel radioiodinated analogues of naturally-occurring cholestrol esters, arylaliphatic cholesteryl ethers, are selective for low density lipoproteins and have been shown to be successful imaging agents for adrenal glands. The arylaliphatic cholesteryl ethers have the general formula: ##STR1## where X is a radioactive isotope of iodine and n is an integer between 1 and 20. Two illustrative examples, m-iodobenzyl cholesteryl ether and 12-(m-iodophenyl) dodecyl cholesteryl ether, were radiolabeled with 125 I by an isotope exchange reaction. Tissue distribution studies indicate significant accumulation of the cholesteryl ethers in the adrenal glands, and to a lesser extent in the liver. The cholesteryl ethers selectively incorporate into plasma lipoproteins as determined by polyacrylamide gel electrophoresis.

Noninvasive Assessment of Lipid Disposition in Treated and Untreated Atherosclerotic Rabbits

In an effort to visualize whole body cholesteryl ester (CE) deposition using the nuclear medicine imaging technique of gamma camera scintigraphy, 125I-cholesteryl iopanoate (125I-CI), a nonhydrolyzable CE analogue, was used as a marker for CE deposition in atherosclerotic New Zealand white rabbits. Groups of animals were fed either a cholesterol-enriched diet (2%, w/w) or the same diet supplemented with the hypolipidemic drugs colestipol (1%, w/w) and/or clofibrate (0.3%, w/w). Injections of 125I-CI were administered biweekly. At the end of 15 weeks, animals were scintigraphically scanned and sacrificed for tissue analysis. The results demonstrated that while drug treatment had no significant effect on plasma lipid levels, it substantially lessened atherosclerotic involvement in the thoracic-abdominal aorta. These differences in aortic lipid accumulation were reflected in the whole-body scans which showed a reduction in tissue accumulation of 125I-CI in the drug-treated groups. Gamma camera scintigraphy thus represents a rapid means of visualizing tissue CE accumulation which could facilitate the evaluation of lipid-lowering drug efficacy and possible antiatherosclerotic effect.

Computed tomography scanning of morris hepatomas with liver-specific polyiodinated triglycerides

RATIONALE AND OBJECTIVES We compared the computed tomography (CT) scanning characteristics of a polyiodinated triglyceride analog with those of a urographic agent to distinguish Morris-7777 hepatoma (MH) cells from normal hepatocytes in rats. METHODS Eighteen Buffalo rats were laparotomized and MH cells injected directly into the hepatic parenchyma or introduced via the portal vein to produce, respectively, focal or diffuse lesions in the liver. Baseline CT scans were obtained 21 days after implantation and prior to intravenous administration of either the polyiodinated triglyceride (45-100 mg I/kg) or the nonionic contrast agent, iohexol (560 mg I/kg). Images were obtained at 0-3 hr and 24 hr. Gross pathologic inspection was performed to validate the imaging results. RESULTS Hepatomas were nearly isodense with normal liver parenchyma in many of the animals, rendering lesion detection difficult with no contrast agent. The bolus administration of iohexol improved lesion detection in many cases. Lesion conspicuity, however, was significantly improved with the polyiodinated triglyceride at less than one eighth the dose of iohexol. CONCLUSION Because of their biochemical nature, polyiodinated triglyceride analogs are specifically cleared by the liver. Consequently, they offer several advantages over nonspecific urographic agents in their ability to enhance lesion conspicuity in this hepatoma model.

Biodistribution of a new lipid-soluble CT contrast agent. Evaluation of cholesteryl iopanoate in the rabbit.

Cholesteryl iopanoate, the prototype for a new class of lipid-soluble, site-specific contrast agents, has undergone preliminary evaluation for organic-specific uptake. This report describes the tissue distribution profile of this radioiodinated sterol ester in the rabbit as a function of time following intravenous injection of tracer doses. Selective accumulation of this agent in the liver and adrenal was observed relative to blood and other tissues. Maximum contrast concentration was achieved between 24 and 48 hours postinjection. Analysis of lipid extra of liver, adrenal, and plasma indicated that the compound was relatively resistant to hydrolysis and dehalogenation. The hepatic selectivity and retention of cholesteryl iopanoate support further study of this or related agents for site-specific, contrast-enhanced computed tomography.

Potential tumor or organ imaging agents—31. Radioiodinated sterol benzoates and carbamates

A series of radioiodinated benzoate and carbamate esters of cholesterol and pregnenolone wherein the acyl moiety served as the carrier for radioiodine was synthesized and evaluated as potential imaging agents for the adrenal cortex. 2,6-Dimethyl-3-iodobenzoyl and N-(4-iodophenyl) carbamoyl groups were chosen as the acyl functionality in an attempt to provide esters resistant to in vivo hydrolysis. Tissue disposition studies in rats revealed that their biodistribution was determined by the attached sterol carrier-the cholesterol esters demonstrated significant uptake at 24 h in the adrenal whereas the corresponding pregnenolone derivatives showed only slight affinity for steroid-secreting tissues at this time.

Radioiodinated Cholesteryl lopanoate as a Potential Probe for the in Vivo Visualization of Atherosclerotic Lesions in Animals.

Radioiodinated cholesteryl iopanoate, a nonhydrolyzable cholesteryl ester probe, showed increased uptake into atherosclerotic aortas of cholesterol-fed rabbits in comparison with normal rabbits. Auto-radiography of the aortas showed the radioactivity to be concentrated in areas of visible atherosclerotic involvement. Lipid extraction and thin-layer chromatography of this tissue as well as liver, adrenal, and plasma confirmed the resistance of this probe to hydrolysis. These findings suggest that 125I-cholesteryl iopanoate may prove useful for noninvasively monitoring atherosclerosis in intact laboratory animals.

Lipid Soluble Contrast Agents for Computed Tomography of the Liver: Results with Cholesteryl Iopanoate

A new class of compounds, polyiodinated sterol esters, has recently been synthesized and found to have characteristics suggesting potential value as site-specific hepatic computed tomographic (CT) contrast agents. A prototype compound, cholesteryl iopanoate, was administered intravenously to rabbits in doses of 65 mg I/kg. The compound was found to significantly enhance hepatic parenchyma to a maximal level of 65 Hounsfield units (HU) above base-line values without observable splenic enhancement. A subsequent study comparing the administered dose with the change in CT attenuation values of liver demonstrated that near-maximum enhancement reaching 22 HU was achieved at a dose of 30 mg I/kg within 24 h after injection. The enhancement characteristics suggest the mechanism of hepatic accumulation may not be mediated solely by the reticuloendothelial system. Administration of cholesteryl iopanoate (30 mg I/kg) to rabbits with hepatic tumors (V x 2 adenocarcinoma) resulted in the CT imaging of tumors as small as 2 mm in diameter. Further investigation of this new class of lipid-soluble contrast agents seems warranted.

FATE OF INTRAVENOUSLY ADMINISTERED HIGH-DENSITY LIPOPROTEIN LABELED WITH RADIOIODINATED CHOLESTERYL OLEATE IN NORMAL AND HYPOLIPIDEMIC RATS

Radioiodinated cholesteryl oleate (125I-CO) was found to associate rapidly with plasma lipoproteins following intravenous administration to rats. The high-density lipoprotein (HDL) fraction was observed to contain the highest amount of radioiodinated ester. Isolation and purification of this HDL fraction (125I-CO-HDL) and subsequent administration to rats demonstrated a plasma clearance similar to that previously observed for HDL labeled by direct iodination. Moreover, the concentration of radioactivity appearing in the adrenal cortex and ovary 0.5 h after intravenous administration of 125I-CO-HDL was greater than that observed after administration of 125I-CO, and the uptake of radioactivity by these tissues was considerably greater in hypolipidemic rats. These findings are consistent with existing knowledge relating to the metabolic fate of HDL and radioiodinated cholesterol derivatives in the rat, and suggest that radioiodinated cholesteryl esters may become useful probes for labeling lipoproteins.

Potential Organ or Tumor Imaging Agents. 32. A Triglyceride Ester of p-Iodophenyl Pentadecanoic Acid as a Potential Hepatic Imaging Agent

A triglyceride analog, glycerol-2-palmitoyl-1,3-di-15-(p-iodophenyl)pentadecanoate (DPPG) was synthesized and radiolabeled for evaluation as a potential functional liver scintigraphic agent. Uptake of DPPG was compared in normal, diabetic, tumor-bearing and heparin pretreated rats, revealing differences in uptake and clearance of radioactivity, correlating with hepatic lipase activity of these groups. Similar results were observed by gamma-camera scintigraphy. Comparing the uptake of DPPG with that of its fatty acid component, 15-(p-iodophenyl)pentadecanoic acid (IPPA), revealed that the peak uptake of IPPA in the liver was about half that of DPPG. Based upon these findings, DPPG warrants further study as a hepatic radiodiagnostic agent.

Esters of iopanoic acid as liver-specific CT contrast agents: biodistribution and CT evaluation

The synthesis and preliminary biodistribution data for a series of sterol-like esters of iopanoic acid having potential value as liver-specific CT contrast agents are described. Structural modification of the sterol portion of the iopanoate ester afforded a group of compounds that displayed tissue specificity similar to chqlesteryl iopanoate, the prototype ester of this series, but were rapidly cleared from the target tissues after hydrolysis. From the biodistribution data, the most promising of these agents, pregnenolone iopanoate (PI), was evaluated by CT in rabbits receiving a radiologic dose equivalent to 30 mg I/kg. The hepatic parenchyma was enhanced within 2 h of infusion to a maximal level of 31 HU above precontrast values. Hepatic CT attenuation returned to normal within 24 h. However, CT performed after PI infusion into Vx2 tumor-bearing rabbits failed to provide superior images compared with those acquired following bolus administration of urographic contrast.